Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
207 SEK | -2.36% | -13.19% | +0.49% |
Mar. 13 | Probi AB Strengthens Its Brand Position and Expands in the Nordics | CI |
Jan. 26 | Transcript : Probi AB, Q4 2023 Earnings Call, Jan 26, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 148.25 and 128.48 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.36 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.49% | 231M | C+ | ||
+30.83% | 687B | C+ | ||
+29.77% | 595B | B | ||
-0.17% | 378B | C+ | ||
+14.98% | 316B | C+ | ||
+11.39% | 308B | B- | ||
+0.51% | 211B | B- | ||
-6.61% | 208B | A+ | ||
-3.70% | 203B | B+ | ||
-3.86% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Probi AB - Nasdaq Stockholm
- Ratings Probi AB